Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
https://doi.org/10.14341/DM9603
Abstract
In recent years, the options in treatment of diabetes mellitus type 2 have substantially expanded (currently more than 40 molecules are approved), however, the number of patients with decompensation of diabetes for the period from 2003 to 2014 remains unchanged. In clinical guidelines injecting drugs are given the «final» role as the most effective drugs. However in clinical trials injecting drugs showed a lower adherence compared to oral drugs. Currently injectable glucose lowering drugs include not only insulin but also analogues of glucagon-like peptide-1 (aGLP-1). However, majority of studies of treatment compliance in type 2 diabetes mellitus considered only insulin. Reasons of low compliance are: 1) offering comprehensive programmes for education, monitoring and patient support by primary care physicians; 2) addressing cost and availability issues; 3) prescribing current insulin, also in combination with GLP-1 agonists; 4) use of more simple and convenient devices for injecting insulin.
About the Authors
Olesya Y. GurovaI.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
MD, PhD
Competing Interests:
Чтение лекций для компаний Boeringer Ingelheim, EliLilly, NovoNordisk, Takeda, Sanofi.
Valentin V. Fadeev
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
MD, PhD, Professor
Competing Interests:
Лектор, участник экспертных советов компаний Boeringer Ingelheim, EliLilly, NovoNordisk, Takeda, Sanofi, Berlin-Chemie, MSD, Merck
Ekaterina S. Maloletkina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
References
1. Carls G, Huynh J, Tuttle E, et al. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Ther. 2017;8(4):863-873. doi: 10.1007/s13300-017-0280-5
2. National Committee for Quality Assurance. The State of Health Care Quality Report 2015. Washington: National Committee for Quality Assurance; 2015.
3. de Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80(1):47-56. doi: 10.1111/cen.12119
4. Doggrell SA, Warot S. The association between the measurement of adherence to anti-diabetes medicine and the HbA1c. Int J Clin Pharm. 2014;36(3):488-497. doi: 10.1007/s11096-014-9929-6
5. DiBonaventura M, Wintfeld N, Huang J, Goren A. The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs. Patient Prefer Adherence. 2014;8:873-882. doi: 10.2147/PPA.S55550
6. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26(1):231-238. doi: 10.1185/03007990903421994
7. Bradley C, Eschwege E, de Pablos-Velasco P, et al. Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes. Diabetes Care. 2018;41(2):267-276. doi: 10.2337/dc16-2655
8. Zhang L, Zakharyan A, Stockl KM, et al. Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes. J Med Econ. 2011;14(5):562-567. doi: 10.3111/13696998.2011.598200
9. Тронько Н.Д., Соколова Л.К., Власенко М.В., Костюкевич А.А. Достижение целей лечения пациентами с сахарным диабетом в Украине. Результаты Международного исследования по изучению практики ведения сахарного диабета (IDMPS) // Эндокринология. — 2015. — Т. 20. — №4. — С. 658-668. [Tronko ND, Sokolova LK, Vlasenko MV, Kostyukevich AA. Dostizhenie tseleĭ lecheniya patsientami s sakharnym diabetom v Ukraine. Rezul'taty Mezhdunarodnogo issledovaniya po izucheniyu praktiki vedeniya sakharnogo diabeta (IDMPS). Endocrinologiya. 2015;20(4):658-668. (In Russ.)]
10. Kaluani R, Cannon C, Cherrington A, et al. Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers. Clin Diabetes. 2018;36(1):14-37. doi: 10.2337/cd17-0119
11. Rajagopalan R, Joyce A, Ollendorf D, Murray FT. Pdb5: Medication Compliance in Type 2 Diabetes Subjects: Retrospective Data Analysis. Value Health. 2003;6(3):328. doi: 10.1016/s1098-3015(10)64171-x
12. He X, Chen L, Wang K, et al. Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis. Patient Prefer Adherence. 2017;11:237-245. doi: 10.2147/PPA.S123389
13. Yavuz DG, Bilen H, Sancak S, et al. Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-naive type 2 diabetes patients: dropout study. Patient Prefer Adherence. 2016;10:851-861. doi: 10.2147/PPA.S100626
14. Bonafede M. A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence. 2010:147. doi: 10.2147/ppa.s10467
15. Korb-Savoldelli V, Gillaizeau F, Pouchot J, et al. Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens (Greenwich). 2012;14(7):429-434. doi: 10.1111/j.1751-7176.2012.00634.x
16. Plakas S, Mastrogiannis D, Mantzorou M, et al. Validation of the 8-Item Morisky Medication Adherence Scale in Chronically Ill Ambulatory Patients in Rural Greece. Open J Nurs. 2016;06(03):158-169. doi: 10.4236/ojn.2016.63017
17. Farsaei S, Radfar M, Heydari Z, et al. Insulin adherence in patients with diabetes: risk factors for injection omission. Prim Care Diabetes. 2014;8(4):338-345. doi: 10.1016/j.pcd.2014.03.001
18. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011;27(6):1169-1174. doi: 10.1185/03007995.2011.573623
19. Khan H, Lasker SS, Chowdhury TA. Prevalence and reasons for insulin refusal in Bangladeshi patients with poorly controlled Type 2 diabetes in East London. Diabet Med. 2008;25(9):1108-1111. doi: 10.1111/j.1464-5491.2008.02538.x
20. Polinski JM, Smith BF, Curtis BH, et al. Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ. 2013;39(1):53-65. doi: 10.1177/0145721712467696
21. Iversen MM, Nefs G, Tell GS, et al. Anxiety, depression and timing of insulin treatment among people with type 2 diabetes: Nine-year follow-up of the Nord-Trondelag Health Study, Norway. J Psychosom Res. 2015;79(4):309-315. doi: 10.1016/j.jpsychores.2015.07.004
22. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications. 2007;21(4):220-226. doi: 10.1016/j.jdiacomp.2006.02.004
23. Skovlund SE, Peyrot M. The Diabetes Attitudes, Wishes, and Needs (DAWN) Program: A New Approach to Improving Outcomes of Diabetes Care. Diabetes Spectr. 2005;18(3):136-142. doi: 10.2337/diaspect.18.3.136
24. Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417. doi: 10.2337/dc13-0331
25. Grant RW, Wexler DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care. 2007;30(6):1448-1453. doi: 10.2337/dc06-2499
26. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-689. doi: 10.1111/j.1464-5491.2012.03605.x
27. Polinski JM, Kim SC, Jiang D, et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc). BMC Endocr Disord. 2015;15:46. doi: 10.1186/s12902-015-0044-z
28. Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications. 2015;29(2):295-301. doi: 10.1016/j.jdiacomp.2014.11.018
29. Polonsky WH, Fisher L, Guzman S, et al. Psychological Insulin Resistance in Patients With Type 2 Diabetes: The scope of the problem. Diabetes Care. 2005;28(10):2543-2545. doi: 10.2337/diacare.28.10.2543
30. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009(164):6-10. doi: 10.1111/j.1742-1241.2009.02176.x
31. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35(6):1014-1022. doi: 10.1177/0145721709345773
32. Schaper NC, Nikolajsen A, Sandberg A, et al. Timing of Insulin Injections, Adherence, and Glycemic Control in a Multinational Sample of People with Type 2 Diabetes: A Cross-Sectional Analysis. Diabetes Ther. 2017;8(6):1319-1329. doi: 10.1007/s13300-017-0317-9
33. Ortiz LG, Berry DC, Ruiz OC, et al. Understanding basic carbohydrate counting, glycemic index, and glycemic load for improved glycemic control in Hispanic patients with type 2 diabetes mellitus. Hisp Health Care Int. 2014;12(3):138-145. doi: 10.1891/1540-4153.12.3.138
34. Vidal Flor M, Jansa Morato M, Galindo Rubio M, Penalba Martinez M. Factors associated to adherence to blood glucose self-monitoring in patients with diabetes treated with insulin. The dapa study. Endocrinol Diabetes Nutr. 2018;65(2):99-106. doi: 10.1016/j.endinu.2017.10.005
35. Zhang Y, Ting RZ, Yang W, et al. Depression in Chinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherence. J Diabetes. 2015;7(6):800-808. doi: 10.1111/1753-0407.12238
36. Bibeau WS, Fu H, Taylor AD, Kwan AY. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes. J Manag Care Spec Pharm. 2016;22(11):1338-1347. doi: 10.18553/jmcp.2016.22.11.1338
37. Khunti K, Nikolajsen A, Thorsted BL, et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401-409. doi: 10.1111/dom.12626
38. Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20(3):488-496. doi: 10.1111/dom.13132
39. Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119-1133. doi: 10.1007/s12325-014-0166-0
40. Spain CV, Wright JJ, Hahn RM, et al. Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. Clin Ther. 2016;38(7):1653-1664 e1651. doi: 10.1016/j.clinthera.2016.05.009
41. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771
42. Cefalu WT, Buse JB, Del Prato S, et al. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care. 2014;37(9):2647-2659. doi: 10.2337/dc14-1395
43. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. doi: 10.7573/dic.212283
44. Malmenas M, Bouchard JR, Langer J. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 mug. Clin Ther. 2013;35(6):795-807. doi: 10.1016/j.clinthera.2013.03.021
45. Lipska KJ, Yao X, Herrin J, et al. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. Diabetes Care. 2017;40(4):468-475. doi: 10.2337/dc16-0985
46. Petrak F, Herpertz S, Stridde E, Pfutzner A. Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin. Diabetes Technol Ther. 2013;15(8):703-711. doi: 10.1089/dia.2012.0257
47. Pittas AG, Westcott GP, Balk EM. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(11):886-894. doi: 10.1016/s2213-8587(15)00280-6
48. Rosenstock J, Fonseca V, Schinzel S, et al. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. J Diabetes Complications. 2014;28(5):742-749. doi: 10.1016/j.jdiacomp.2014.04.003
49. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. doi: 10.1056/NEJMoa1203858
50. Eby EL, Wang P, Curtis BH, et al. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. J Med Econ. 2013;16(4):529-538. doi: 10.3111/13696998.2013.772059
51. Giugliano D, Maiorino MI, Bellastella G, et al. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510-517. doi: 10.2337/dc10-1710
52. Kallenbach L, Shui AM, Cheng WY, et al. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting. Endocr Pract. 2018;24(9):805-814. doi: 10.4158/EP-2017-0261
53. Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care. 2016;39(11):2026-2035. doi: 10.2337/dc16-0917
54. Buse JB, Gough SC, Woo VC, et al. 1.1 IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial (65-OR). Nederlands Tijdschrift voor Diabetologie. 2015;11(3):74-75. doi: 10.1007/s12467-013-0026-6
55. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463-473. doi: 10.1111/dom.12090
56. Davis NJ, Wylie-Rosett J. Death to carbohydrate counting? Diabetes Care. 2008;31(7):1467-1468. doi: 10.2337/dc08-0807
57. Dungan KM, Sagrilla C, Abdel-Rasoul M, Osei K. Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes. Diabetes Care. 2013;36(11):3476-3482. doi: 10.2337/dc13-0121
58. Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848. doi: 10.1016/s0149-2918(03)80337-5
59. Wright BM, Bellone JM, McCoy EK. A review of insulin pen devices and use in the elderly diabetic population. Clin Med Insights Endocrinol Diabetes. 2010;3:53-63. doi: 10.4137/CMED.S5534
60. Smallwood C, Lamarche D, Chevrier A. Examining Factors That Impact Inpatient Management of Diabetes and the Role of Insulin Pen Devices. Can J Diabetes. 2017;41(1):102-107. doi: 10.1016/j.jcjd.2016.07.001
61. Burdick P, Cooper S, Horner B, et al. Use of a subcutaneous injection port to improve glycemic control in children with type 1 diabetes. Pediatr Diabetes. 2009;10(2):116-119. doi: 10.1111/j.1399-5448.2008.00449.x
62. Blevins T, Schwartz SL, Bode B, et al. A Study Assessing an Injection Port for Administration of Insulin. Diabetes Spectr. 2008;21(3):197-202. doi: 10.2337/diaspect.21.3.197
63. Khan A, Alswat K. The benefits of using the I-port system on insulin-dependent patients. Journal of Nutrition and Human Health. In: Proceedings of the International conference on Diabetes, Nutrition, Metabolism and Medicare; Vancouver, 2017 Jul 24-26.
64. Conget I, Castaneda J, Petrovski G, et al. The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study. Diabetes Technol Ther. 2016;18(1):22-28. doi: 10.1089/dia.2015.0159
65. Chlup R, Runzis S, Castaneda J, et al. Complex Assessment of Metabolic Effectiveness of Insulin Pump Therapy in Patients with Type 2 Diabetes Beyond HbA1c Reduction. Diabetes Technol Ther. 2018;20(2):153-159. doi: 10.1089/dia.2017.0283
66. Vidal Florc M, Jansà Morató M, Galindo Rubio M, Penalba Martínez M. Factors associated to adherence to blood glucose self-monitoring in patients with diabetes treated with insulin. The dapa study. Endocrinol Diabetes Nutr. 2018;65(2):99-106. doi: 10.1016/j.endien.2018.02.002
67. Brod M, Alolga SL, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. Patient. 2014;7(4):437-450. doi: 10.1007/s40271-014-0068-x
68. Майоров А.Ю., Суркова Е.В., Мотовилин О.Г., и др. Обучение больных диабетом: синтез доказательной медицины и психологического подхода // Сахарный диабет. — 2011. — Т. 14. — №1. — С. 46-50. [Mayorov AY, Surkova EV, Motovilin OG, et al. Education of diabetic patients: synthesis of evidence-based medicine and psychological approach. Diabetes mellitus. 2011;14(1):46-50. (In Russ.)] doi: 10.14341/2072-0351-6249
69. Grillo Mde F, Neumann CR, Scain SF, et al. Effect of different types of self-management education in patients with diabetes. Rev Assoc Med Bras (1992). 2013;59(4):400-405. doi: 10.1016/j.ramb.2013.02.006
70. Cani CG, Lopes LS, Queiroz M, Nery M. Improvement in medication adherence and self-management of diabetes with a clinical pharmacy program: a randomized controlled trial in patients with type 2 diabetes undergoing insulin therapy at a teaching hospital. Clinics. 2015;70(2):102-106. doi: 10.6061/clinics/2015(02)06
71. Boels AM, Vos RC, Hermans TGT, et al. What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? An observational study in eight European countries. BMJ Open. 2017;7(7):e016180. doi: 10.1136/bmjopen-2017-016180
72. Loskutova NY, Tsai AG, Callen E, et al. Differences in perspectives regarding diabetes management between health care providers and patients. Transl Behav Med. 2018;8(3):328-340. doi: 10.1093/tbm/iby024
73. Horigan G, Davies M, Findlay-White F, et al. Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review. Diabet Med. 2017;34(1):14-26. doi: 10.1111/dme.13120
74. Pal K, Eastwood SV, Michie S, et al. Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;(3):CD008776. doi: 10.1002/14651858.cd008776
75. Murray E, Sweeting M, Dack C, et al. Web-based self-management support for people with type 2 diabetes (HeLP-Diabetes): randomised controlled trial in English primary care. BMJ Open. 2017;7(9):e016009. doi: 10.1136/bmjopen-2017-016009
76. Pun SPY, Coates V, Benzie IFF. Barriers to the self-care of type 2 diabetes from both patients’ and providers’ perspectives: literature review. J Nurs Healthc Chronic Illn. 2009;1(1):4-19. doi: 10.1111/j.1365-2702.2008.01000.x
77. Schaper NC, Nikolajsen A, Sandberg A, et al. Timing of Insulin Injections, Adherence, and Glycemic Control in a Multinational Sample of People with Type 2 Diabetes: A Cross-Sectional Analysis. Diabetes Ther. 2017;8(6):1319-1329. doi: 10.1007/s13300-017-0317-9
78. Knight KM, McGowan L, Dickens C, Bundy C. A systematic review of motivational interviewing in physical health care settings. Br J Health Psychol. 2006;11(Pt 2):319-332. doi: 10.1348/135910705X52516
79. Bhaloo T, Juma M, Criscuolo-Higgins C. A solution-focused approach to understanding patient motivation in diabetes self-management: Gender differences and implications for primary care. Chronic Illn. 2018;14(4):243-255. doi: 10.1177/1742395317736372
80. Welch G, Zagarins SE, Santiago-Kelly P, et al. An internet-based diabetes management platform improves team care and outcomes in an urban Latino population. Diabetes Care. 2015;38(4):561-567. doi: 10.2337/dc14-1412
81. Kempf K, Altpeter B, Berger J, et al. Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2017;40(7):863-871. doi: 10.2337/dc17-0303
82. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. Lancet. 2010;376(9748):1261-1271. doi: 10.1016/s0140-6736(10)60809-4
83. Baig AA, Benitez A, Quinn MT, Burnet DL. Family interventions to improve diabetes outcomes for adults. Ann N Y Acad Sci. 2015;1353:89-112. doi: 10.1111/nyas.12844
84. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review. Diabet Med. 2014;31(7):773-786. doi: 10.1111/dme.12452
85. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240-245. doi: 10.2337/dc09-1348
86. Bibeau WS, Fu H, Taylor AD, Kwan AY. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes. J Manag Care Spec Pharm. 2016;22(11):1338-1347. doi: 10.18553/jmcp.2016.22.11.1338
87. Yao S, Lix L, Shevchuk Y, et al. Reduced Out-of-Pocket Costs and Medication Adherence – A Population-Based Study. J Popul Ther Clin Pharmacol. 2018;25(1):e1-e17. doi: 10.22374/1710-6222.25.1.1
88. Furler J, O'Neal D, Speight J, et al. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ. 2017;356:j783. doi: 10.1136/bmj.j783
89. van Bruggen R, Gorter K, Stolk R, et al. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract. 2009;26(6):428-436. doi: 10.1093/fampra/cmp053
Supplementary files
Review
For citations:
Gurova O.Y., Fadeev V.V., Maloletkina E.S. Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence. Diabetes mellitus. 2018;21(6):524-533. (In Russ.) https://doi.org/10.14341/DM9603
Views:
35333
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
